Literature DB >> 11745402

Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS.

J S Mo1, J W Streilein.   

Abstract

Since immune privilege is believed to exist in the eye in order to suppress sight-destroying inflammation, we wondered whether eyes with intraocular inflammation retain the immune privileged state. Intraocular inflammation was induced by injection of lipopolysaccharide (LPS) into the vitreous cavity of BALB/c mouse eyes, which showed a peak in intensity at approximately 9 h. At this time point, inflamed eyes were examined for their capacity to afford immune privilege to injected allogeneic tumor cells, and to promote anterior chamber-associated immune deviation (ACAID) to antigens injected locally. In addition, aqueous humor (AqH) harvested from inflamed eyes was tested for its ability to suppress T cell activation. Surprisingly, eyes with acute, intense intraocular inflammation allowed allogeneic tumor cells to form progressively growing tumors, and these same eyes promoted ACAID. Moreover, AqH harvested from inflamed eyes strongly inhibited T cell activation. We conclude that the type of extreme, intraocular inflammation evoked by intravitreally injected LPS fails to abolish immune privilege in the eye. These findings are discussed in light of the effects of other types of inflammation on the integrity of ocular immune privilege, and with respect to the capacity of the eye to maintain immune privilege by more than one mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745402     DOI: 10.1002/1521-4141(200112)31:12<3806::aid-immu3806>3.0.co;2-m

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Corneal stromal cells selectively inhibit production of anti-inflammatory cytokines by activated T cells.

Authors:  V Holán; A Vítová; J Pindjáková; M Krulová; A Zajícová; M Filipec
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

2.  IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

3.  A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid.

Authors:  Ru Zhou; Reiko Horai; Mary J Mattapallil; Rachel R Caspi
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 4.  Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates.

Authors:  Ravid Shechter; Anat London; Michal Schwartz
Journal:  Nat Rev Immunol       Date:  2013-03       Impact factor: 53.106

5.  Retinal laser burn-induced neuropathy leads to substance P-dependent loss of ocular immune privilege.

Authors:  Kenyatta Lucas; Dimitris Karamichos; Rose Mathew; James D Zieske; Joan Stein-Streilein
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

6.  Aqueous humor suppression of dendritic cell function helps maintain immune regulation in the eye during human uveitis.

Authors:  Alastair K Denniston; Paul Tomlins; Geraint P Williams; Sherine Kottoor; Imran Khan; Kadambari Oswal; Mike Salmon; Graham R Wallace; Saaeha Rauz; Philip I Murray; S John Curnow
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

7.  The living eye "disarms" uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition.

Authors:  Ru Zhou; Reiko Horai; Phyllis B Silver; Mary J Mattapallil; Carlos R Zárate-Bladés; Wai Po Chong; Jun Chen; Rachael C Rigden; Rafael Villasmil; Rachel R Caspi
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

8.  Total protein concentration and T-cell suppression activity of aqueous humour before and after penetrating keratoplasty.

Authors:  J-S Mo; P Maier; D Böhringer; H Reinshagen; R Sundmacher; T Reinhard
Journal:  Eye (Lond)       Date:  2011-11-18       Impact factor: 3.775

9.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

10.  Understanding autoimmunity in the eye: from animal models to novel therapies.

Authors:  Rachel R Caspi
Journal:  Discov Med       Date:  2014-03       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.